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Platelets and Blood Cells  
High on-treatment platelet reactivity by more than one agonist  
predicts 12-month follow-up cardiovascular death and non-fatal  
myocardial infarction in acute coronary syndrome patients receiving 
coronary stenting 
Rossella Marcucci1,2; Anna Maria Gori1–3; Rita Paniccia1,2; Betti Giusti1,2; Serafina Valente2; Cristina Giglioli2;  
Piergiovanni Buonamici2; David Antoniucci1; Rosanna Abbate1; Gian Franco Gensini1–3 
1Department of Medical and Surgical Critical Care, University of Florence; Centre for the study at molecular and clinical level of chronic, degenerative and neoplastic diseases to 
develop novel therapies, University of Florence, Florence, Italy; 2Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; 3Centro S.Maria agli 
Ulivi, Fondazione Don Carlo Gnocchi Onlus IRCCS, Impruneta, Florence, Italy 
Summary 
There is some data available on the role of high on-treatment platelet 
reactivity by ADP whereas, as regards arachidonic acid or other agon-
ists, there is no proof of the best cut-off for identifying populations with 
a different cardiovascular outcome by the construction of appropriate 
receiver-operator characteristics (ROC) curves. We enrolled 1,108 acute 
coronary syndrome patients undergoing percutaneous coronary inter-
vention (PCI) with stent implantation and followed them up for 12 
months. Platelet reactivity was assessed by light transmission aggrego-
metry (LTA) using 10 μM ADP, 1 mM arachidonic acid (AA) and 2 μg/ml 
collagen. At a 12-month follow-up, we found 37 cardiovascular deaths 
(3.3%), 54 non-fatal myocardial infarctions (MI) (4.8%) and 154 target 
vessel revascularisations (TVR) (13.8%). ROC analysis demonstrated 
that 10 μM ADP LTA, 1 mM AA and 2 μg/ml collagen LTA were able to 
distinguish between patients with and without subsequent cardiovas-
cular death and non-fatal MI (area under the curve for 10 μM ADP 0.63 
(0.55–0.71), p<0.001; for 1 mM AA 0.68 (0.61–0.76), p<0.0001; for 2 
μg/ml collagen 0.62 (0.52–0.73), p<0.0111), whereas no association 
was demonstrated with the occurrence of TVR. Ten μM ADP LTA ≥55%, 
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1 mM AA LTA ≥15% and 2 μg/ml collagen LTA ≥31% were identified as 
the optimal cut-off to predict cardiovascular death and non-fatal MI at 
12-month follow-up. The contemporary platelet hyperreactivity to more 
than one agonist was associated with a higher risk of 12-month cardio-
vascular death and MI, whereas isolated platelet hyperreactivity to only 
one agonist had not a predictive value [10 μM ADP LTA ≥55% + 1 mM 
AA LTA ≥15%: odds ratio [OR]=3.6(2.4–6.1), p<0.0001; ADP LTA ≥55% 
+ 1 mM AA LTA ≥15% + 2 μg/ml collagen LTA ≥31%: OR=4.7(2.9–7.7), 
p<0.0001]. In this prospective study on a large number of acute coron-
ary syndrome patients undergoing stent implantation, we have found 
that high on-treatment platelet reactivity measured by LTA induced by 
more than one agonist – AA, ADP, collagen – is an independent risk fac-
tor for 12-month cardiovascular death and non-fatal MI. Isolated pla-
telet hyperreactivity to only one agonist has not a predictive value for 
clinical recurrences. 
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Introduction 
A growing body of evidence is demonstrating that the biological 
entity of high on-treatment platelet reactivity is associated with an 
increased risk of adverse cardiovascular events, such as stent 
thrombosis, cardiovascular (CV) death and non-fatal myocardial 
infarction (MI) (1–4). The majority of available studies has been 
performed on a limited number of patients and has restricted the 
analysis on the responsiveness to a single agonist. Several data are 
available on the role of high on-treatment platelet reactivity by 
adenosine diphosphate (ADP) (5–11) whereas, as regards arachi-
donic acid (AA) or other agonists, there is no proof of the best cut-
off for identifying populations with a different cardiovascular out-
come by the construction of appropriate receiver-operating char-
acteristics (ROC) curves (12–19). Furthermore, several data ob-
tained on chronic, stable cardiovascular patients are sapped by the 
postulate that non compliance may be the major practical reason 
for high on-treatment platelet reactivity. With this regards, it is 
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critical to separate the available evidence in acute and chronic set-
tings.  
This is a large prospective study planned to evaluate the clinical 
impact of high on-treatment platelet reactivity measured by light 
transmittance aggregometry (LTA) induced by AA, ADP and col-
lagen on the occurrence of major adverse coronary events in the 
setting of acute coronary syndrome (ACS) patients undergoing 
stent implantation. We have found, by the construction of appro-
priate ROC analysis, the optimal cut-off points for the detection of 
patients at risk of clinical recurrences. 
Materials and methods 
Study population 
Patients with ACS who underwent PCI and with an anticipated 
compliance to dual antiplatelet treatment for 12 months were con-
sidered eligible for the study. Informed written consent was ob-
tained from all patients, and the study was approved by the local 
Ethical Review Board. Six hundred and eighty-three patients were 
included in a previous prospective study for the evaluation of the 
clinical impact of platelet reactivity measured by a point-of-care 
system (11). 
PCI and antiplatelet management 
All interventions were performed according to current standard 
guidelines, and the type of stent implanted and the use of IIb/IIIa 
inhibitors were at discretion of the operator. All patients received 
one clopidogrel loading dose of 600 mg followed by a daily dose of 
75 mg. All patients received unfractioned heparin 70 IU/Kg during 
the procedure and acetylsalicylic acid i.v. 500 mg followed by a 
daily dose of 100–325 mg by oral route according to the current 
guidelines for PCI (20).  
Platelet reactivity assessment  
Venous blood samples anticoagulated with 0.109 M sodium citrate 
(ratio 9:1) were taken from each patient within 24 hours from 600 
mg clopidogrel loading. For patients receiving in the catheteri-
sation laboratory both the loading dose of clopidogrel and a IIb/
IIIa inhibitor, blood samples were obtained six days later while the 
patient was on the 75 mg maintenance dose of clopidogrel. 
Platelet-rich plasma, obtained by centrifuging whole blood for 
10 minutes (min) at 200 g, was stimulated with 10 μM ADP (Mas-
cia Brunelli, Milan, Italy), with 1 mM AA (Sigma-Aldrich, Milan, 
Italy) and with 2 μg/ml collagen and aggregation was assessed 
using a APACT 4 light transmission aggregometer (Helena Labora-
tories, Milan, Italy) as previously reported (21).  
Data collection and follow-up 
All data were prospectively collected and entered into a central da-
tabase. Clinical follow-up information was obtained by contacting 
all patients at 12 months and source documents of potential events 
were obtained.  
Endpoints: 1) CV death, defined as death in the presence of 
acute coronary syndrome, significant cardiac arrhythmia or re-
fractory chronic heart failure (CHF); 2)non-fatal MI (a rise in 
serum troponin I and/or an increase in creatine kinase MB 
isoenzyme at least twice the upper normal limits with at least one 
of the following: acute onset of prolonged (≥20 min) typical is-
chaemic chest pain; ST-segment elevation of at least 1 mm in two 
or more contiguous electrocardiographic leads or ST-depression 
of ≥0.5 mm in ≥2 contiguous leads; 3) target vessel revasculari-
sation (TVR) ( need for repeat PCI or coronary artery bypass graft-
ing). 
Statistical analysis 
Continuous variables are presented as median (range). Categorical 
data are reported as frequencies. Differences in continuous vari-
ables were compared by Student’s t test or Mann-Whitney U test, as 
appropriate. Dichotomous variables were compared by chi-square 
test or Fisher’s Exact test, as appropriate.  
A ROC analysis was used to determine the ability of 10 μM ADP, 
1 mM AA and 2 μg/ml collagen LTA to distinguish between pa-
tients with and without post-discharge events after PCI. The opti-
mal cut-off point was calculated by determining the post-treat-
ment LTA value that provided the greatest sum of sensitivity and 
specificity. Cumulative survival curves for both patients with and 
without high on-treatment platelet reactivity (as defined by 10 μM 
ADP LTA ≥55%, 1 mM AA LTA ≥15% and 2 μg/ml collagen LTA 
≥31%, cut-off calculated by ROC analysis) were constructed by the 
Kaplan-Meier method, and the log-rank sum test was used to as-
sess the statistical differences between these two survival curves. 
Univariate and multivariate regression analyses were used, respect-
ively, to identify risk factors for clinical end points and to adjust for 
potential confounders [cardiovascular risk factors, renal failure, 
left ventricular ejection fraction <40%, multivessel disease, total 
stent length, bifurcation lesions, number of lesions treated and 
type of stent (bare-metal stent [BMS] or drug-eluting stent [DES]), 
use of GpIIb/IIIa inhibitors, aspirin dosage]. McNamer test was 
used to compare specificity between different aggregometry tests. 
A significant level was defined when p<0.05. All analysis was per-
formed using SPSS 10.0 (SPSS Inc., Chicago, IL, USA). 
Results 
From January 2005 to February 2007, a total of 1,108 patients were 
enrolled in the present study. Baseline characteristics are shown in 
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 Overall group 
(n=1108) 
12 month  
follow-up MACE  
(n=91) 
12 month  
follow up  
no -MACE (n=1017)  
P-value° 
Age, years 69 (32–94) 69 (42–90) 69 (32–94) 0.006 
Male gender, n (%) 836 (75.4) 27 (29.7) 245 (24.1) 0.1  
Diabetes, n (%) 266 (24.0)  25 (27.5) 241 (23.7) 0.3  
Smoking, n (%) 390 (35.2)  35 (38.5)  355 (34.9) 0.3 
Hypertension, n (%) 730 (65.9)  59 (64.8)  671 (66) 0.4  
Dyslipidaemia, n (%) 613 (55.3) 49 (53.8)  564 (55.5) 0.4  
Family history of CAD, n (%) 121 (10.9) 5 (5.5)  116 (11.4) 0.005 
LVEF<40%, n (%) 281 (25.4) 29 (31.9)  252 (24.8) 0.01 
Renal failure*, n (%) 102 (9.2)  9 (9.9)  93 (9.1) 0.4  
STEMI, n (%) 413 (37.3) 35 (38.5)  378 (37.2) 0.4 
LTA by 1 mM AA 20.3 ± 21.7 32.4 ± 27.6 19.2 ± 20.8 0.001 
LTA by 2 μg/ml collagen 29.2 ± 22.5 39.6 ± 26.6 28.3 ± 21.9 0.001 
Renal insufficiency defined by creatinine levels above 2.0 mg/dl. °= MACE (CV death and nonfatal MI) vs. no MACE. For abbrevi-
ations see text. 
ACE-inhibitors, n (%) 753 (67.9) 62 (68.1) 691 (67.9) 0.9  
Beta-blockers, n (%) 454 (40.9) 37 (40.6) 417 (41) 0.8 
Statins, n (%) 698 (62.9) 57 (62.6) 641 (63) 0.8 
Pump inhibitors, n (%) 1030 (92.9) 84 (92.3) 946 (93) 0.8 
Glycoprotein IIb/IIIa, n (%) 443 (39.9)  35 (38.4) 408 (40.1) 0.5  
Lesions treated, n 2032 166 1866 …  
Vessels treated, n 1639 179 1460  … 
Drug-eluting stents, n (%) 181 (16.3) 20 (22) 161 (15.8) 0.2  
Bifurcation lesions, n (%) 467 (42.1)  39 (42.8) 428 (42) 0.6 
Total stent length, mm 35 ± 23.4 37.6 ± 28.4 34.8 ± 22.9 0.4  
LTA by 10 μM ADP 47.1 ± 21.4 55.6 ± 21.0 46.4 ± 21.3 0.001 
Table 1: Clinical char-




(ROC) curve for light 
transmission aggrego-
metry (LTA) induced by 
AA, ADP and collagen. 
Table 1. The 12-month follow-up rate was 100%. A total of 254 
clinical recurrences were recorded: 37 CV deaths (3.3%), 54 non-
fatal MI (4.8%) and 154 TVR (13.8%). 10 μM ADP LTA, 1 mM AA 
and 2 μg/ml collagen LTA values were significantly higher in pa-
tients with the subsequent occurrence of CV death and non-fatal 
MI (Table 1) whereas no differences were detected among patients 
with or without TVR (10 μM ADP LTA: 45.5 ± 20.7% vs. 47.4 ± 
21.5%, p=0.1;1 mM AA: 20.8 ± 24% vs. 20.1 ± 21.3%, p=0.1; 2 μg/
ml collagen: 28.2 ± 23.2% vs. 29.4 ± 22.4%, p=0.2). Clinical char-
acteristics according to the occurrence of CV deaths and non-fatal 
MI are reported in Table 1.  
ROC curve analysis demonstrated that 10 μM ADP LTA, 1 mM 
AA and 2 μg/ml collagen LTA were able to distinguish between pa-
tients with and without subsequent CV death and non-fatal MI at 
12-month follow-up (area under the curve [AUC] for 10 μM ADP 
0.63 (0.55–0.71), p<0.001; for 1 mM AA 0.68 (0.61–0.76), 
p<0.0001; for 2 μg/ml collagen 0.62 (0.52–0.73), p<0.0111) (Fig. 
1), whereas no association was demonstrated with the occurrence 
of TVR (AUC for 10 μM ADP 0.47 (0.42–0.52), p=0.09; for 1 mM 
AA 0.48 (0.43–0.53), p=0.09; for 2 μg/ml collagen 0.48 
(0.43–0.53), p=0.08).  
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 10 μM ADP 1 mM AA 2 μg/ml  
collagen 
10 μM ADP 
+ 2 μg/ml  
collagen 
10 μM ADP 
+ 1 mM AA 
10 μM ADP 
+ 1 mM AA 
+ 2 μg/ml  
collagen 
Sensitivity 59(49–69) 62(51–71) 67(57–77) 53(42–63) 49(39–60) 45(35–55) 
Specificity 63(51–66) 68(65–71) 68(65–70) 78(76–81) 80*(77–82) 85*^(83–87) 
Positive predictive value 13(9–15) 15(11–18) 16(12–19) 18(13–22) 18(13–23) 21(15–27) 
Negative predictive value 95(93–96) 95(94–97) 96(94–97) 95(93–96) 95(93–96) 95(93–96) 
°p<0.001 vs. 10 μM ADP. *p<.0001 vs. 10 μM ADP, vs. 1 mM AA and vs. 2 μg/ml collagen; ^ p<0.001 vs. 10 μM ADP +  
1 mM AA. For abbreviations see text. 
Table 2: Sensitivity, 
specificity, positive 
and negative predic-
tive values of light 
transmission aggrego-
metry (LTA) in predict-
ing cardiovascular (CV) 
death and non-fatal 
myocardial infarction 
(MI). 
Table 3: Clinical characteristics according to platelet reactivity. 
 10 μM ADP  
LTA ≥55% 
(n=432) 





Age, years 69 (46–93) 68 (33–94) <0.01 
Male gender, n (%) 315 (73) 523 (78.4) <0.01 
Diabetes, n (%) 118 (27.3) 143 (21.4) <0.001 
Smoking, n (%) 147 (34) 2408369 0.4 
Hypertension, n (%) 306 (70.8) 422 (63.3) 0.6 
Statins, n (%) 274 (63.4) 418 (62.6) 0.2 
Pump inhibitors, n (%) 403 (93.3) 618 (92.6) 0.3 
Glycoprotein IIb/IIIa, n (%) 176 (40.7) 269 (40.3) 0.4 
Lesion treated, n 823 1204 … 
Vessels treated, n 659 971 … 

















































Dyslipidaemia, n (%) 228 (52.7) 385 (56.9) 0.2 0.5 239 (54.2) 374 (56.1) 0.5 
Family history of CAD, n (%) 47 (10.8) 74 (10.9) 0.1 0.4 40 (9.1) 81 (12.6) 0.3 
LVEF<40%, n (%) 118 (27.3) 163 (24.1) <0.001 <0.001 118 (26.7) 163 (24.4) <0.001 
Renal failure*, n (%) 34 (7.8) 68 (10) 0.4 0.5 39 (8.8) 63 (9.4) 0.2 
STEMI, n (%) 197 (45.6) 216 (31.9) <0.001 <0.001 182 (41.2) 231 (34.2) <0.001 
ACE-inhibitors, n (%) 293 (67.8) 460 (68) 0.3 0.4 297 (67.3) 456 (68.3) 0.1 
Beta-blockers, n (%) 177 (40.9) 277 (40.9) 0.3 0.3 183 (41.5) 271 (40.6) 0.1 
Drug-eluting stents, n (%) 94 (21.7) 87 (12.8) <0.01 <0.01 80 (18.1) 101 (15.1) <0.01 
Bifurcation lesions, n (%) 182 (42.1) 285 (42.1) 0.2 0.3 198 (44.9) 269 (40.3) 0.2 
Total stent length, mm 37.9 ± 25.6 33.4 ± 21.7 <0.01 <0.01 38.4 ± 26.8 33.6 ± 22 <0.01 






















36.5 ± 23.2 























Ten μM ADP LTA ≥55%, 1 mM AA LTA ≥15% and 2 μg/ml col-
lagen LTA ≥31% were identified as the optimal cut-off to predict 
CV death and non-fatal MI at 12-month follow-up. The contem-
porary hyperreactivity to both AA and ADP LTA (AA LTA ≥15% + 
ADP LTA ≥55%) and the hyperreactivity to three agonists (AA LTA 
≥15% + ADP LTA ≥55% + collagen LTA ≥31%) resulted in a higher 
specificity and positive predictive values for detection of 12-month 
CV death and non-fatal MI whereas negative predictive values 
were similar. Sensitivity, specificity, positive and negative predic-
tive values for the different aggregometry tests are reported in 
Table 2.  
Clinical characteristics according to platelet reactivity are 
shown in Table 3. Patients with high on-treatment platelet reactiv-
ity (defined according to ROC-based cut-off) were significantly 
older, more likely to be female, diabetics, with a diagnosis of ST-
elevation myocardial infarction (STEMI), with a reduced ejection 
fraction than patients without hyperreactivity. Interestingly, we 
have observed that the total stent length and the number of DES 
were significantly higher in patients with high on-treatment pla-
telet reactivity. No differences were detected among these clinical 
and procedural characteristics according to the type of agonist 
used. 
The event-free survival curves for CV death and non-fatal MI 
according to the presence of residual platelet reactivity (RPR) by 
different agonists are shown in Figures 2, 3 and 4. 
At univariate analysis, 10 μM ADP LTA ≥55%, 1 mM AA LTA 
≥15% and 2 μg/ml collagen LTA ≥31% were associated with a sig-
nificant higher risk of CV death and non-fatal MI, whereas no sig-
nificant associations were detected with TVR (Table 4). The con-
temporary presence of platelet hyperreactivity by AA, ADP and 
collagen was associated with a higher risk for CV death and non-
fatal MI (Table 4). These results were confirmed after adjustment 
for confounding variables (cardiovascular risk factors, renal fail-
ure, reduced ejection fraction, multivessel disease, total stent 
length, bifurcation lesions, number of lesions treated, type of stent 
used, use of glycoprotein IIb/IIIa inhibitors and aspirin dosage) 
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Figure 2: Survival free from cardiovascular (CV) death and non-fatal 
myocardial infarction (MI) in patients with and without AA LTA ≥15%. 
Figure 3: Survival free from cardiovascular death and non-fatal myo-
cardial infarction (MI) in patients with and without ADP-LTA ≥55%. 
Figure 4: Survival free from cardiovascular (CV) death and non-fatal 
myocardial infarction (MI) in patients with and without % collagen 
LTA ≥31%. 
[10 μM ADP LTA ≥55%: odds ratio [OR]=2.4 (1.6–3.8), p<0.0001; 
1 mM AA LTA ≥15%: OR=3.0 (1.8–5.3), p<0.0001; 2 μg/ml col-
lagen LTA ≥31%: OR=2.4 (1.5–3.9), p<0.0001; 10 μM ADP LTA 
≥55% + 1 mM AA LTA ≥15%: OR=3.6 (2.4–6.1), p<0.0001; ADP 
LTA ≥55% + 1 mM AA LTA ≥15% + 2 μg/ml collagen LTA ≥31%: 
OR=4.7 (2.9–7.7), p<0.0001]. 
Discussion 
In this prospective study on a large number of ACS patients under-
going stent implantation, we have found that high on-treatment 
platelet reactivity measured by LTA induced by more than one 
agonist – AA, ADP, collagen – is an independent risk factor for 
12-month CV death and non-fatal MI, and that isolated platelet 
hyperreactivity to only one agonist has not a predictive value for 
clinical recurrences. 
The strength of our results is based on: 1) the definition of the 
cut-off points on the basis of the clinical recurrences by the con-
struction of ROC curves; 2) the large number of patients enrolled; 
3) the length of follow-up. 
Furthermore, with respect to data available in the literature, as 
regards AA or other agonists than ADP, there is no proof of the best 
cut-off for identifying populations with a different cardiovascular 
outcome by the construction of appropriate ROC curves. Indeed, 
published studies have investigated platelet function induced by a 
single agonist (5–11, 13–15, 17–19), on a limited number of pa-
tients (14, 17, 19) and using an ‘a priori’ cut-off calculated on the 
distribution in controls (13–15, 17–19). No study has calculated a 
cut-off of AA- or collagen-induced platelet function based on a 
ROC curve (i.e. on the basis of cardiovascular recurrences) or has 
contemporaneously investigated platelet function induced by dif-
ferent agonists. 
By using different agonists which reflect different pathways of 
platelet function, we have demonstrated that ACS patients with a 
12-month recurrence have an ‘aggressive’ platelet, independently of 
the responsiveness to a single antiplatelet drug. We evaluated pla-
telet function by using three agonists – AA, ADP and collagen. AA-
induced platelet aggregation is mainly influenced by the inhibition 
of the thromboxane synthesis and ADP-induced platelet aggre-
gation is mainly sensitive to the inhibition of ADP receptors, both 
P2Y1 and P2Y12. However, evidence exists of the role of the P2Y12 
receptor, target of clopidogrel, as a functional regulator of TxA2 
generation consequent to protein-activated receptor stimulation 
(22) and/or, conversely, the fact that ADP- and collagen- induced 
platelet aggregation are affected to some extent by aspirin (23). 
Collagen interacts with integrin α2β1 and glycoprotein VI (GPVI) 
and triggers intracellular signals that shift platelet integrins to a 
high-affinity state and induce the release of the secondary medi-
ators ADP and TXA2 (24). Therefore, even if a single agonist may 
mainly reflect a single pathway of platelet function, there is an im-
portant overlap between the different pathways activated by the 
three agonists. The consequence is that, beyond the activation of a 
single pathway and the responsiveness to a single drug, the finding 
of a high on treatment platelet reactivity using different agonists 
identifies a hyperactive platelet which is not adequately inhibited by 
the dual antiplatelet treatment. The translation of this finding into 
the clinical practice remains to be evaluated. The history of the 
antiplatelet therapy in acute coronary syndrome patients under-
going PCI moves from the use of a single drug – aspirin -, to the 
dual antiplatelet therapy – aspirin and clopidogrel – and finally to 
the loading dose of clopidogrel (firstly 300 mg and secondly 600 
mg) followed by a dual daily antiplatelet therapy. This history is yet 
ongoing as new antiplatelet drugs, such as prasugrel which has a 
more intense and rapid antiplatelet effect, have been found to re-
duce thrombotic risk in this setting even if at the price of an in-
creased bleeding risk (25). Our data demonstrate that ACS patients 
who die or experience a MI after the percutaneous revasculari-
sation are characterised by the presence of an hyperactive platelet, 
on top of the optimal standard antiplatelet therapy. It is conceiv-
able that these patients might take advantage from a more intense 
antiplatelet therapy – higher dosage of the current drugs or the ad-
dition of a third antiplatelet agent (10, 26, 27, 28) – without an in-
creased bleeding risk. Recent data obtained by the oral PAR-1 an-
tagonist SCH 530348 are in line with this hypothesis [29]. On the 
other hand, retrospective analyses of trials such as PCI-CURE or 
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Table 4: Clinical outcome at 12-month follow-up according to platelet reactivity.










10 μM ADP LTA ≥55% 
(n=432) 
54(12.5) 2.4(1.6–3.8) 0.001 52(12) 0.8(0.5–1.1) 0.3 
1 mM AA LTA ≥15% (n=379) 56(14.7) 3.4(2.2–5.3) 0.001 49(12.9) 0.9(0.6–1.3) 0.4 
2 μg/ml collagen LTA ≥31% (n=441) 42(9.5) 2.4(1.5–3.9) 0.001 51(11.6) 0.9(0.6–1.2) 0.4 
10 μM ADP LTA ≥55% 
+ 2 μg/ml collagen LTA ≥31% 
(n=269) 
48(17.8) 4.0(2.6–6.2) 0.001 31(11.5) 0.9(0.6–1.3) 0.4 
10 μM ADP LTA ≥55% 
+ 1 mM AA LTA ≥15% (n=251) 
45(17.9) 3.8(2.5–5.9) 0.001 31(12.3) 0.8(0.5–1.3) 0.3 
10 μM ADP LTA ≥55% 
+ 1 mM AA LTA ≥15%  
+2 μg/ml collagen LTA ≥31% (n=194) 
41(21.1) 4.6(2.9–7.2) 0.001 26(13.4) 0.9(0.6–1.5) 0.4 
Isolated 10 μM ADP LTA ≥55% (n=113) 9(7.9) 0.9(0.5–1.9) 0.5 14(12.4) 0.9(0.5–1.5) 0.4 
Isolated 1 mM AA LTA ≥15% (n=57) 5(8.8) 1.1(0.4–2.7) 0.4 8(14) 1.0(0.5–2.2) 0.5 
Isolated 2 μg/ml collagen LTA ≥31% (n=44) 0 - - 7(15.9) 1.2(0.5–2.6) 0.5 
Patients with LTA values equal or above the reported cut-off vs. patients with LTA values less than the reported cut-off. For abbreviations see text. 
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CHARISMA suggest that daily aspirin doses higher than 100 mg 
are not associated with clear benefit and may cause harm com-
pared with lower doses (75 or 81 mg/day). This datum is not 
against our findings of a correlation between worse outcome and 
residual platelet reactivity. We have found that a global high on-
treatment platelet reactivity is associated with a worse clinical out-
come; subsequently, we will have to evaluate the better treatment, 
if any, to overcome this hyperreactivity.  
The results of this study, obtained in patients with ACS and with 
a 12-month follow-up, are in keeping with those obtained in the 
RECLOSE trial (30), underlying the role of high on-treatment pla-
telet reactivity in the setting of ACS patients undergoing PCI. 
We are aware that platelet reactivity at the time of ACS may be 
influenced by a number of clinical and laboratory parameters, in-
cluding the high level of the inflammatory state and the increased 
platelet turnover. Consequently a percentage of patients with pla-
telet hypereactivity in the acute state might subsequently return to 
an adequate platelet inhibition. The issue of the durability of high 
on-treatment platelet reactivity remains to be solved by ad hoc 
studies. Nevertheless, our results underline the concept that an ‘ag-
gressive’ platelet characterises patients at higher risk of clinical re-
currences, even if this laboratory finding might not be stable over 
time. In other words, an aggressive platelet at the time of the acute 
event identifies, together with procedural and clinical character-
istics, high-risk patients for which a tailored antiplatelet therapy 
might be useful. 
Furthermore, we have to take into account the possible con-
founding role that patient non-adherence has on individual anti-
platelet response as evidence indicates its impact in the real-world 
setting. 
What is known about this topic?  
● High on-clopidogrel platelet reactivity by ADP has been associated 
with an increased risk of cardiovascular events in patients under-
going dual antiplatelet treatment. 
● As regards arachidonic acid (AA) or other agonists, there is no 
proof of the best cut-off for identifying populations with a different 
cardiovascular outcome by the construction of appropriate receiv-
er-operating curves.  
What does this paper add? 
● In this prospective study on a large number of acute coronary syn-
drome patients undergoing stent implantation, we have found that 
high on-treatment platelet reactivity measured by light trans-
mission aggregometry induced by more than one agonist – AA, 
ADP, collagen – is an independent risk factor for 12-month cardio-
vascular death and non-fatal myocardial infarction, and that iso-
lated platelet hyperreactivity to only one agonist has not a predic-
tive value for clinical recurrences. 
● The strenght of our results depends on: 1) the definition of the cut-
off points on the basis of the clinical recurrences by the construc-
tion of receiver-operating curves; 2) the large number of patients 
enrolled; 3) the length of follow-up.
LTA, the standard method of platelet function assessment, has lo-
gistic problems which make its routine use difficult. For this reason, 
a number of assays for platelet reactivity by different methods and 
agonists are under laboratory and clinical evaluation, also by our 
group. Most importantly, our findings stress the need of systems for 
the evaluation of platelet function based on the use of multiple agon-
ists able to explore different pathways of platelet function. 
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